​

Funding Round

Series B - ARTHEx Biotech

Series B - ARTHEx Biotech

Investment Firm

Overview

AntagomiR oligonucleotides to treat Myotonic Dystrophy patients.

Announced Date

May 03, 2023

Funding Type

Series B

Highlights

Location

Europe

Social

Investor Lead

Columbus Venture Partners

Columbus Venture Partners

Columbus Venture Partners is a early_stage_venture and late_stage_venture and seed and venture firm.

Participant Investors

6

Investor Name
Participant InvestorSound Bioventures
Participant InvestorColumbus Venture Partners
Participant InvestorCentre for the Development of Industrial Technology (CDTI)
Participant InvestorAdBio partners
Participant InvestorEuropean Innovation Council

Round Details and Background

ARTHEx Biotech raised $46487689 on 2023-05-03 in Series B

AntagomiR oligonucleotides to treat Myotonic Dystrophy patients.

Company Funding History

6

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jun 01, 2020
Seed Round - ARTHEx Biotech
1-1.3M
Oct 14, 2022
Grant - ARTHEx Biotech
1-2.4M
Oct 25, 2022
Venture Round - ARTHEx Biotech
1-11.5M
May 03, 2023
Series B - ARTHEx Biotech
7-46.5M

Recent Activity

There is no recent news or activity for this profile.